The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Open accessAbstract
BACKGROUND: Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODS: We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter over a period of 540 days. The coprimary end points in each trial were the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. RESULTS: A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, respectively. Mean (±SD) LDL cholesterol levels at baseline were 104.7±38.3 mg per deciliter (2.71±0.99 mmol per liter) and 105.5±39.1 mg per deciliter (2.73±1.01 mmol per liter), respectively. At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. CONCLUSIONS: Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Randomized controlled trials, including the VICTORION-Mono and VICTORION-Difference trials, as well as ORION -10, -11, and other Phase III trials, have consistently demonstrated that inclisiran reduces LDL-C compared with placebo in primary and secondary prevention settings.5, 6, 7”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The trials showed that patients achieved LDL-C decreases of 52.3% and 49.9% at Day 510 [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ORION-10 and ORION-11 trials achieved LDL-C reductions greater than 50% among their participants [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The initial injections of inclisiran at Day 1 and 90 followed by biannual maintenance resulted in a long-term average LDL-C reduction of − 44% to − 48% across ORION-1 and ORION-10 and ORION-11 [25, 44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical observations demonstrate that numerous patients stop taking their daily statin medications or PCSK9 antibody injections irregularly which reduces their ability to prevent cardiovascular diseases [44, 80].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 siRNA and monoclonal antibodies blocking the PCSK9/LDLR interaction potently lower LDL cholesterol and reduce the risk of adverse cardiovascular events (Sabatine et al., 2017; Schwartz et al., 2018; Ray et al., 2020).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 inhibitory antibodies and siRNA potently reduce LDL cholesterol to unprecedented low levels and are approved for treatment of hypercholesterolemia.”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeted PCSK9 inhibition restores hepatic LDLR levels, decreases plasma LDL-C levels and improves cardiovascular outcomes.7,9–11”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The phase 3 ORION-10 and ORION-11 trials evaluated inclisiran compared with placebo across a total of 1561 and 1617 patients with atherosclerosis or an atherosclerotic CVD risk-equivalent, respectively [137]. Compared with placebo, inclisiran reduced LDL-C levels by − 52% and − 50%, respectively.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [137]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to monoclonal antibodies that sequester PCSK9 in the circulation and are now prescribed to patients, the small-interfering RNA inclisiran that targets PCSK9 hepatic production has recently been approved, following reports of substantial LDL lowering [50% reduction (95% confidence interval 47–53)] with this drug (11).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9, has demonstrated the ability to reduce LDL cholesterol by 49-52% in trials evaluating individuals with established cardiovascular disease or ASCVD risk equivalent (129).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9 and is referred to as a PCSK9 siRNA in this section, has demonstrated the ability to reduce LDL cholesterol by 49–52% in trials evaluating individuals with established CVD or ASCVD risk equivalent (123).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [123]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran was noted to decrease LDL by ∼50% in the ORION trials [20]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
The cited source says what the claim attributes to it.
In the citing paper
“Large-scale research including well-powered trials such as ORION 10 and ORION 11 demonstrates that Inclisiran shows strong potential as a potent lipid-lowering agent [44].”
In the citing paper
“Patients on statins with high LDL-C levels and ASCVD or at least one ASCVD risk equivalent were included in the two phase 3 trials ORION-10 and ORION-11 (Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol), and obtained a further 50% reduction of LDL-C with inclisiran.278”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [278]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationRodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4936 · Cited by 347
The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications
Choudhry, N. K., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiß, S., Pakes, J., Brennan, T. A., & Shrank, W. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.495 · Cited by 314
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,007
CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo
Fan, G., Guo, W. P., Lu, J., He, Y., Zha, J., Zhang, Q., Chen, Y., Tan, D., 唐志晗, Yang, J., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156485 · Cited by 6
Wiegman, A., Peterson, A. L. H., Bruckert, É., Defesche, J. C., Schweizer, A., Bergeron, J., Chueca, M. J., van Lennep, J. E. R., Santos, R. D., Schwab, K. O., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00351-1 · Cited by 6
The evolving therapeutic landscape of PCSK9 inhibition
Mansfield, B. S., Bene-Alhasan, Y. O., Ballantyne, C. M., & Raal, F. J. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120670 · Cited by 7
Self-citationPradhan, A. K., Thandi, P., Mahajan, K., Iellamo, F., Perrone-Filardi, P., & Perrone, M. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.059 · Cited by 6
Vega, R. B., O’Mahony, G., Barbour, A., Yu, H., Knöchel, J., Brengdahl, J., Hochdörfer, T., Bergenholm, L., Carlsson, E. T., Ahnmark, A., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.075973 · Cited by 6
Steg, P. G., Goodman, S. G., Jukema, J. W., Martens, P., Zirlik, A., Bhatt, D. L., Menon, V., Szarek, M. J., Lesogor, A., Stratz, C., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107493 · Cited by 7
A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia
Mousa, E. A., Al-Azzam, S. I., Araydah, M., Karasneh, R. A., Ghnaimat, M. A., Al-Makhamreh, H. K., Khawaldeh, A., Al-Samen, M. A. A., HADDAD, J. A., Najjar, S. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134312 · Cited by 8
Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
Mirzai, S., Chevli, P. A., Rikhi, R. R., & Shapiro, M. D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411311 · Cited by 8
PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
Zhou, L., Zhang, H., Wang, S., Zhao, H., Li, Y., Han, J., Zhang, H., Li, X., & Qu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1327185 · Cited by 8
Dyslipidemia and peripheral arterial disease
Yadav, A. K., Sawant, V., Bedi, V. S., & Yadav, K. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.010 · Cited by 9
You, M., Tian, M., Song, Z., Liu, Z., Yang, B., & Zhang, S. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03609 · Cited by 6
de Angelis, C. D., Meddeb, M., Chen, N., & Fisher, S. A. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00745.2023 · Cited by 7
Is there a role for earlier use of combination therapy?
Revankar, S., Park, J. K., Satish, P., & Agarwala, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100639 · Cited by 6
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.03.002 · Cited by 6
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review
Sinha, M., Maged, R., Tarar, P., Bandi, V. V., Koneru, H. M., & Sarwar, H. (2024) · Cureus · doi:10.7759/cureus.69824 · Cited by 6
Lamia, T. H., Shah-Riar, P., Khanam, M., Khair, F., Sadat, A., Tania, M. K., Haque, S. M., Saaki, S. S., Ferdausi, A., Naurin, S. A., et al. (2024) · Cureus · doi:10.7759/cureus.71365 · Cited by 8
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 9
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies
Gao, R., Liu, M., Yang, H., Shen, Y., & Xia, N. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1548355 · Cited by 6
He, Y., Li, H., Shi, Q., Liu, Y., Pan, Q., & He, X. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07401-w · Cited by 6
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
Zhang, L., Li, B., Chen, W., Li, W., Yang, H., & Pan, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25248 · Cited by 9
Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
Belančić, A., Štiglić, M. K., Prgomet, L., Pećin, I., Reiner, Ž., & Vitezić, D. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70122 · Cited by 6
Managing the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Current Evidence and Future Directions of PCSK9 Inhibition
Xu, J., & Shapiro, M. D. (2021) · US Cardiology Review · doi:10.15420/usc.2020.17 · Cited by 7
The promise and challenges of RNA-targeted therapeutics in preventive cardiology
Arsenault, B. J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab462 · Cited by 6
Does test anxiety and gender have an impact on OSCE Performance among medical students?
Arain, F. R. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94165 · Cited by 6
Wilson, P. M., Dixon, S., Vell, T., Bower, P., Rootkin, L., Williams, C., Strong, A., Lawrence, D., Elvey, R., Williams, O., et al. (2023) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20231106 · Cited by 6
The Societal Impact of Inclisiran in England: Evidence From a Population Health Approach
Ostwald, D. A., Schmitt, M., Peristeris, P., Gerritzen, T., & Durand, A. (2023) · Value in Health · doi:10.1016/j.jval.2023.05.002 · Cited by 6
Genetics-based risk scores for prediction of premature coronary artery disease
Gupta, R. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.08.003 · Cited by 7
Modern algorithms for statin therapy
Susekov, A. V. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5594 · Cited by 6
Paragh, G., Zilahi, P., Kolozsvári, L. R., Lőrincz, H., Fülöp, P., & Harangi, M. (2024) · Life · doi:10.3390/life14030374 · Cited by 6
He, Y., Guan, X., Zhang, Y., Zhu, Z., Zhang, Y., Feng, Y., & Li, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2348562 · Cited by 8
Cancer biology functional genomics: From small RNAs to big dreams
Rajan, S. S., Ludwig, K. R., Hall, K. L., Jones, T. L., & Caplen, N. J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23260 · Cited by 6
Ulashchik, E. A., Martynenko-Makaev, Y. V., Akhlamionok, T. P., Melnik, D. M., Shmanai, V. V., & Zatsepin, T. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_7 · Cited by 7
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
ADAMTS7 Knockdown in Context: Emerging Therapeutic Targets in Atherothrombosis
Feinstein, M. J., & Thorp, E. B. (2021) · Circulation Research · doi:10.1161/circresaha.121.319722 · Cited by 6
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“Large-scale research including well-powered trials such as ORION 10 and ORION 11 demonstrates that Inclisiran shows strong potential as a potent lipid-lowering agent [44].”
InfluentialMaliha, M., Satish, V., Kumar, S. S., Chi, K. Y., Shama, N., Kharawala, A., Duarte, G., Li, W., Purkayastha, S., Mangeshkar, S., et al. (2025) · Healthcare · doi:10.3390/healthcare13020141 · Cited by 6
Genetics of Calcific Aortic Stenosis: A Systematic Review
Vassiliou, V. S., Johnson, N. J., Langlands, K., & Tsampasian, V. (2024) · Genes · doi:10.3390/genes15101309 · Cited by 5
“Inclisiran: Early LDL-C target achievement in a real-life population”
Briani, F., Bagli, M., Venturi, G., Bacchion, F., & Mugnolo, A. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.01.001 · Cited by 5
The Potential of RNA Therapeutics in Treating Cardiovascular Disease
Mainkar, G., Ghiringhelli, M., & Zangi, L. (2025) · Drugs · doi:10.1007/s40265-025-02173-1 · Cited by 6
McLain, A., Kowalczyk, A. M., Rachwalska, P., Sutera, F. M., Robertson, L. J., Nielsen, N. S., Enghild, J. J., Cobice, D., Bonelli, F., Barbaro, V., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113681 · Cited by 5
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Hurwitz, M., Agboola, O. J., Gami, A., Williams, M. S., Virani, S. S., Sharma, G. V., & Patel, J. (2025) · US Cardiology Review · doi:10.15420/usc.2024.33 · Cited by 10
Insights from a real-world experience with inclisiran at a large United States lipid clinic
Mazdeyasnan, D., Birs, A. S., Chiou, T. T., Diano, L., & Wilkinson, M. J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.015 · Cited by 5
Labinaz, A., Yao, R., Hosseini, F., Turgeon, R. D., Marchand, M., Brunham, L. R., Hawkins, N. M., Wong, G. C., Mancini, G. B. J., & Fordyce, C. B. (2025) · CJC Open · doi:10.1016/j.cjco.2025.06.021 · Cited by 5
Wang, J., Qu, J., Ye, M., Feng, R., Hui, X., Yang, X., Jin, J., Tong, Q., Zhang, X., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101416 · Cited by 8
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
Razavi, A. C., & Shapiro, M. D. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101314 · Cited by 6
Nowacka, A., Śniegocki, M., & Ziółkowska, E. (2025) · Cells · doi:10.3390/cells14181479 · Cited by 5
Optimizing the targeting of lipid nanoparticles for gene therapy
Yue, L., Gao, X., Qi, W., Zhang, L., & Wang, Y. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00351b · Cited by 6
Non-cationic carriers for siRNA delivery: Current progress and potential applications
Fan, M., Yang, X., Liu, Y., Xia, X., Ismail, M., & Zheng, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114362 · Cited by 5
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 6
RNA Therapeutics in Heart Failure
Deiman, F. E., de Graaf, M. M., Silljé, H. H. W., Beverborg, N. G., Bömer, N., & van der Meer, P. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10717-9 · Cited by 6
Zhou, H., Lu, J., Yin, B., Meng, Y., Zhu, C., Wu, X., Liu, J., Zhu, Q., Tai, Z., & Chen, Z. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202504232 · Cited by 5
Tanaka, A., Oyama, K., Yakushiji, Y., Natsuaki, M., Mizuno, A., Saito, Y., Matsumoto, S., Yamagami, H., Kunieda, T., Shibata, S., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65908 · Cited by 6
Inclisiran in Patients with CKD
Landmesser, U., Ray, K. K., Raal, F. J., Conde, L. G., Han, J., Köenig, W., Leiter, L., Schwartz, G. G., Wright, R. S., & on behalf of the KCHF Study Investigators (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001006 · Cited by 5
Self-citationTang, J., Gong, D., Li, H., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.039 · Cited by 6
Crintea, A., Bocșan, I. C., Jianu, M. E., Şovrea, A. S., Munteanu, C., Kubelac, P. M., Craciun, A. M., & Silaghi, C. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062311 · Cited by 5
Efficacy and safety of oral Pcsk9 inhibitors: insights from a meta-analysis of RCTs
Olmastroni, E., Xie, S., Galimberti, F., Catapano, A. L., & Casula, M. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag273 · Cited by 6
Research progress and development strategies of antibody-oligonucleotide conjugates
Fan, W., Luan, W., Yu, W., Li, Y., Wei, C., Liu, X., Ni, L., Cao, H., Fang, C., & Fu, Y. (2026) · Gene Therapy · doi:10.1038/s41434-026-00621-5 · Cited by 7
Nanomaterial-enabled RNA therapeutics: bridging delivery barriers to clinical translation
Pandey, K., Jha, S., Chaliha, L. B., Gosai, H. B., & Patel, R. (2026) · Frontiers in Nanotechnology · doi:10.3389/fnano.2026.1860221 · Cited by 7
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Self-citationLehoux, D. E., Kallend, D. G., Wijngaard, P. L. J., Brown, A. P., & Zerler, B. R. (2023) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1080 · Cited by 4
Self-citationOptimal Medical Therapy for Stable Ischemic Heart Disease in 2024
Abrahams, T., Nicholls, S. J., & Nelson, A. J. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.12.005 · Cited by 5
Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
Kratky, V., Valerianova, A., Hruskova, Z., Tesař, V., & Malík, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01191-w · Cited by 5
Sapina, A. I., Varlamova, Y. Y., Papyrina, M. G., Bezymyanny, A. S., Kordzaya, E. L., & Vasilyeva, E. Y. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5943 · Cited by 5
Cancro, F. P., Bellino, M., Silverio, A., Maio, M. D., Esposito, L., Palumbo, R., Manna, M., Formisano, C., Ferruzzi, G. J., Vecchione, C., et al. (2024) · Translational Medicine UniSa · doi:10.37825/2239-9747.1058 · Cited by 5
Rajendran, Y., Nandhakumar, M., Eerike, M., Kondampati, N., Mali, K. R., Chalissery, L. F., Konda, V. G. R., & Nagireddy, U. M. (2024) · Cureus · doi:10.7759/cureus.69900 · Cited by 7
de Kermenguy, C., Durand, A., Tollenaere, Q., Pabic, E. L., Paillard, F., & Mahé, G. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04289-w · Cited by 5
Current and future role of PCSK9 inhibitors in ASCVD prevention
Greco, A., & Capodanno, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2450189 · Cited by 5
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Liu, S., Wang, X., Hu, J., Zhao, C., & Qin, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16355 · Cited by 7
Chemoprevention of hepatocellular carcinoma using N-acetylgalactosamine-conjugated siRNAs
Maggiore, G., Hsieh, M.-H., Bellary, A., Gopal, P., Li, L., Guo, J., Hsiehchen, D., Dadali, T., Broom, W. J., Maier, M. A., et al. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052370 · Cited by 6
Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
Polychronopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1839417 · Cited by 5
Diagnostik und Therapie von statinassoziierten Muskelsymptomen
Kassner, U., Grunwald, S. A., Spira, D., Buchmann, N., Bobbert, T., Gazzerro, E., Hollstein, T., Spuler, S., & Steinhagen‐Thiessen, E. (2021) · Der Internist · doi:10.1007/s00108-021-01059-0 · Cited by 5
Jahangir, A., Sahra, S., & Krzyzak, M. (2021) · Cureus · doi:10.7759/cureus.16664 · Cited by 7
Lipoprotein(a): An update on its role in human health and disease
Koutsogianni, A.-D., Liberopoulos, E. N., & Tselepis, A. D. (2021) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1028 · Cited by 5
Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice
Minami, Y., Kinoshita, D., Muramatsu, Y., Nagata, T., & Ako, J. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.31 · Cited by 5
Clua, A., Grijalvo, S., Erande, N. D., Gupta, S., Yucius, K., Gargallo, R., Mazzini, S., Manoharan, M., & Eritja, R. (2022) · Molecules · doi:10.3390/molecules27123944 · Cited by 5
▼Inclisiran: more hope less hype
(2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2022.000009 · Cited by 5
Update on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Activity-Dependent Non-Coding RNA MAPK Interactome of the Human Epileptic Brain
Kirchner, A., Dachet, F., Lipovich, L., & Loeb, J. A. (2023) · Non-Coding RNA · doi:10.3390/ncrna9010003 · Cited by 5
Allevi, M., Sarnari, S., Giulietti, F., Spannella, F., Pentima, C. D., & Sarzani, R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1181720 · Cited by 5
Chen, K.-C., Hsu, C., Wu, C., Lin, K.-L., Chen, S., Lee, Y.-C., Hsu, C., Hsu, C., Huang, C.-Y., Huang, S.-H., et al. (2023) · PubMed Central · doi:10.6515/acs.202311_39(6).20230921a · Cited by 5
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials
Karakasis, P., Patoulias, D., Barkas, F., Theofilis, P., Milionis, H. J., Doumas, M. N., Kassimis, G., Tsioufis, K. P., & Fragakis, N. (2024) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.06.005 · Cited by 5
Review of Recent Literature and Updates in Nonstatin Cholesterol Management
Wang, E. M., Asias-Dinh, B. D., & Rosario, N. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.001 · Cited by 6
Graf, M., Khera, A. V., May, S. G., Chung, S., N’Dri, L., Cristino, J. R., & Electricwala, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35990 · Cited by 5
Zou, D., Hu, Q., Liu, Y., & Yu, L. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01784-0 · Cited by 5
Lim, Y. L., Tan, R., Poh, K. K., & Wang, X. J. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2024.101067 · Cited by 5
Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry
Briani, F., Sani, E., Venturi, G., Bacchion, F., Balzano, S., Battocchio, M., D'Elia, K., Frigo, G. M., Licchelli, L., Lupo, A., et al. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07749-3 · Cited by 6
Antiviral Therapeutics for Emerging Viruses
Ogidi, O. I., Aye, T., & Felagha, I. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9276-8.ch006 · Cited by 5
Bouvenot, G. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.02.005 · Cited by 7
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Parham, J. S., & Goldberg, A. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01036-4 · Cited by 5
Liuzzo, G., & Patrono, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac360 · Cited by 5
Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach
Grant, J. K., Snow, S. C., Kelsey, M. D., Rymer, J. A., Schaffer, A. E., Patel, M. R., McGarrah, R. W., Pagidipati, N. J., & Shah, N. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01751-z · Cited by 5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5
Grassi, G. M., Pinto, R. D., Rosei, C. A., Agnoletti, D., Borghi, C., Cicero, A. F. G., Ciuceis, C. D., Desideri, G., Grassi, D., Muiesan, M. L., et al. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00501-6 · Cited by 8
Barrios, V., Escobar, C., Anguita, M. P., Arrarte, V., Ruíz, R. C., Cosı́n-Sales, J., Cabello, M. I. E., Martínez, J. M. G., Guijarro, C., Mostaza, J. M., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2021.02.006 · Cited by 5
Kasiewicz, L. N., Biswas, S., Beach, A., Ren, H., Dutta, C., Mazzola, A. M., Rohde, E., Chadwick, A. C., Cheng, C., Musunuru, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.08.467731 · Cited by 5
Yoshiji, S., Lu, T., Butler‐Laporte, G., Carrasco-Zanini, J., Chen, Y., Liang, K. Y. H., Willett, J., Su, C., Wang, S., Adra, D., et al. (2023) · medRxiv · doi:10.1101/2023.04.19.23288706 · Cited by 5
Metadata
- Authors
- Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., & Kastelein, J. J. P.
- Affiliations
- Mayo Clinic (US)
- From the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.); the Department of Cardiology, Mayo Clinic, Rochester, MN (R.S.W.); the Medicines Company, Zurich, Switzerland (D.K.); Deutsches Herzzentrum München, Technische Universität München, and Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, and the Institute of...
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1507-1519
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3012265841
- Semantic Scholar
- 0c86cfdc39f60ff6dc8854a281c1b95f32bdc692
- Cited by
- 1,665
- References
- 19
- Citations by year
- 2026: 296 · 2025: 290 · 2024: 289 · 2023: 273 · 2022: 231 · 2021: 193 · 2020: 87
- FWCI
- 183.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- The Medicines Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- inclisiran, PCSK9 inhibition, LDL cholesterol lowering, atherosclerotic cardiovascular disease, statin therapy, injection-site adverse events, hypercholesterolemia, lipid-lowering therapy, adverse events, drug safety and efficacy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Aged, 80 and over, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypercholesterolemia, Injections, Subcutaneous, Cholesterol, LDL, Liver Function Tests, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
